Pharmigene Past Earnings Performance
Past criteria checks 0/6
Pharmigene's earnings have been declining at an average annual rate of -22.7%, while the Biotechs industry saw earnings growing at 17.8% annually. Revenues have been growing at an average rate of 12.4% per year.
Key information
-22.7%
Earnings growth rate
0.06%
EPS growth rate
| Biotechs Industry Growth | 12.2% |
| Revenue growth rate | 12.4% |
| Return on equity | -14.8% |
| Net Margin | -36.6% |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Pharmigene makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 132 | -48 | 64 | 33 |
| 31 Mar 23 | 133 | -46 | 62 | 32 |
| 31 Dec 22 | 134 | -43 | 59 | 30 |
| 30 Sep 22 | 129 | -40 | 59 | 26 |
| 30 Jun 22 | 125 | -37 | 58 | 22 |
| 31 Mar 22 | 127 | -30 | 56 | 19 |
| 31 Dec 21 | 129 | -23 | 53 | 15 |
| 30 Sep 21 | 120 | -20 | 52 | 12 |
| 30 Jun 21 | 110 | -16 | 52 | 9 |
| 31 Mar 21 | 106 | -13 | 51 | 9 |
| 31 Dec 20 | 101 | -11 | 49 | 9 |
| 30 Sep 20 | 97 | -19 | 48 | 9 |
| 30 Jun 20 | 92 | -27 | 47 | 9 |
| 31 Mar 20 | 79 | -31 | 44 | 11 |
| 31 Dec 19 | 65 | -35 | 41 | 12 |
| 31 Dec 18 | 78 | -13 | 29 | 11 |
| 31 Dec 17 | 55 | -8 | 16 | 8 |
Quality Earnings: 7595 is currently unprofitable.
Growing Profit Margin: 7595 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 7595 is unprofitable, and losses have increased over the past 5 years at a rate of 22.7% per year.
Accelerating Growth: Unable to compare 7595's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 7595 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-13.8%).
Return on Equity
High ROE: 7595 has a negative Return on Equity (-14.81%), as it is currently unprofitable.